A Phase II Trial of Tazemetostat Plus Mosunetuzumab in Untreated Follicular Lymphoma
Latest Information Update: 14 Apr 2025
At a glance
- Drugs Mosunetuzumab (Primary) ; Tazemetostat (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 24 Oct 2023 Planned End Date changed from 1 Sep 2033 to 1 Oct 2033.
- 24 Oct 2023 Planned primary completion date changed from 1 Sep 2033 to 1 Oct 2033.
- 24 Oct 2023 Status changed from not yet recruiting to recruiting.